Abiopharma

CervoMed to Participate in Upcoming Investor Conferences

New real-world data elevating patient perspectives highlight the need for scientific advancement in maternal fetal immunology at ISUOG 2025

LIXTE Biotechnology Holdings Appoints Two New Board Members and New Chief Financial Officer

NuCana to Present Data on NUC-7738’s Synergy with PD-1 Inhibitors at the ESMO Congress 2025

Alcon Completes Acquisition of LumiThera

MIMEDX to Sponsor and Attend Symposium on Advanced Wound Care (SAWC) Fall

LIXTE Biotechnology Holdings Appoints Two New Board Members and New Chief Financial Officer

Cocrystal Pharma to Participate at the H.C. Wainwright Global Investment Conference

New Form 8-K - enGene Holdings Inc. Filed: 2025-09-03 AccNo: 0000950170-25-112674 Size: 1 MB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

ZyVersa Therapeutics Highlights Lipidomic Data in Alport Syndrome and DKD Reinforcing the Need for Drugs to Attenuate Damaging Renal Lipid Accumulation to Mitigate Disease Progression

Phio Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference

New Form 8-K - Wave Life Sciences Ltd. Filed: 2025-09-03 AccNo: 0001193125-25-194511 Size: 181 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

New Form 8-K - Kiniksa Pharmaceuticals International, plc Filed: 2025-09-03 AccNo: 0001104659-25-086689 Size: 8 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Biogen Highlights Multiple Assets and Indications in Lupus

New Form 8-K - Claritev Corp Filed: 2025-09-03 AccNo: 0001793229-25-000151 Size: 6 MB Item 7.01: Regulation FD Disclosure